AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Avenue Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity

AVENUE THERAPEUTICS, INC.

Nasdaq notified Avenue Therapeutics on May 19, 2023, of non-compliance with minimum $2.5M stockholders' equity requirement.
Q1 2023 10-Q reported stockholders' equity of negative $2,157,000.
Company has 45 days (until July 3, 2023) to submit a plan to regain compliance.
No immediate effect on listing; stock continues trading on Nasdaq under ATXI.
Company intends to submit compliance plan and take measures to regain compliance, but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

$2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported stockholders’ equity of negative $2,157,000. The Letter further noted that as of the letter date, the Company did not have a market value of listed securities of $35 million, or net income from continued operations of

View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-063143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.